Karen Byrne serves as the Associate Director of Project Management and Leadership in Oncology at Daiichi Sankyo US, where she leverages her extensive experience in directing complex drug development projects from initiation through to successful closeout. With a proven history of managing fast-paced initiatives, Karen...
Karen Byrne serves as the Associate Director of Project Management and Leadership in Oncology at Daiichi Sankyo US, where she leverages her extensive experience in directing complex drug development projects from initiation through to successful closeout. With a proven history of managing fast-paced initiatives, Karen excels in orchestrating cross-functional teams to drive strategic objectives in the highly competitive pharmaceutical landscape. Her expertise in project management is complemented by her adeptness in data visualization, allowing her to transform complex datasets into actionable business insights that inform decision-making processes.
At Daiichi Sankyo, Karen is currently spearheading key oncology projects that focus on innovative therapies aimed at addressing unmet medical needs. Her role involves not only overseeing project timelines and deliverables but also fostering collaboration among diverse stakeholders, including research and development, regulatory affairs, and commercial teams. This cross-functional leadership is critical in navigating the intricate landscape of drug development, where alignment and strategic thinking are paramount.
In addition to her project management capabilities, Karen brings a wealth of knowledge from her previous experiences in various industries, including lighting and fast-moving consumer goods (FMCG). This diverse background enriches her approach to program management, enabling her to apply best practices from different sectors to enhance operational efficiency and drive business growth. With a strong foundation in strategic planning and process review, Karen is committed to delivering high-quality outcomes that not only meet but exceed organizational goals in the dynamic field of oncology.
